Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
US11058779B2 · kind B2 · utility
15Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2016 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | Dec 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.